Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study
Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The ob...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly |
| Aporte de: |
| id |
todo:paper_0021972X_v95_n11_pE373_Daly |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_0021972X_v95_n11_pE373_Daly2023-10-03T14:25:05Z Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study Daly, A.F. Tichomirowa, M.A. Petrossians, P. Heliövaara, E. Jaffrain-Rea, M.-L. Barlier, A. Naves, L.A. Ebeling, T. Karhu, A. Raappana, A. Cazabat, L. De Menis, E. Montañana, C.F. Raverot, G. Weil, R.J. Sane, T. Maiter, D. Neggers, S. Yaneva, M. Tabarin, A. Verrua, E. Eloranta, E. Murat, A. Vierimaa, O. Salmela, P.I. Emy, P. Toledo, R.A. Sabaté, M.I. Villa, C. Popelier, M. Salvatori, R. Jennings, J. Longás, Á.F. Aizpún, J.I.L. Georgitsi, M. Paschke, R. Ronchi, C. Valimaki, M. Saloranta, C. De Herder, W. Cozzi, R. Guitelman, M. Magri, F. Lagonigro, M.S. Halaby, G. Corman, V. Hagelstein, M.-T. Vanbellinghen, J.-F. Barra, G.B. Gimenez-Roqueplo, A.-P. Cameron, F.J. Borson-Chazot, F. Holdaway, I. Toledo, S.P.A. Stalla, G.K. Spada, A. Zacharieva, S. Bertherat, J. Brue, T. Bours, V. Chanson, P. Aaltonen, L.A. Beckers, A. growth hormone liothyronine octreotide somatomedin C somatostatin derivative thyrotropin thyroxine adult aip gene article cancer invasion clinical assessment controlled study dyspnea female gene mutation genetic predisposition genotype phenotype correlation germ line gigantism growth hormone blood level growth hormone secreting adenoma human human genome hypophysis adenoma hypopituitarism liothyronine blood level major clinical study male onset age priority journal prolactin release prolactinoma repeated drug dose retrospective study tachycardia thyrotropin blood level thyrotropin secreting adenoma thyroxine blood level treatment response tumor volume Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. Copyright © 2010 by The Endocrine Society. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
growth hormone liothyronine octreotide somatomedin C somatostatin derivative thyrotropin thyroxine adult aip gene article cancer invasion clinical assessment controlled study dyspnea female gene mutation genetic predisposition genotype phenotype correlation germ line gigantism growth hormone blood level growth hormone secreting adenoma human human genome hypophysis adenoma hypopituitarism liothyronine blood level major clinical study male onset age priority journal prolactin release prolactinoma repeated drug dose retrospective study tachycardia thyrotropin blood level thyrotropin secreting adenoma thyroxine blood level treatment response tumor volume |
| spellingShingle |
growth hormone liothyronine octreotide somatomedin C somatostatin derivative thyrotropin thyroxine adult aip gene article cancer invasion clinical assessment controlled study dyspnea female gene mutation genetic predisposition genotype phenotype correlation germ line gigantism growth hormone blood level growth hormone secreting adenoma human human genome hypophysis adenoma hypopituitarism liothyronine blood level major clinical study male onset age priority journal prolactin release prolactinoma repeated drug dose retrospective study tachycardia thyrotropin blood level thyrotropin secreting adenoma thyroxine blood level treatment response tumor volume Daly, A.F. Tichomirowa, M.A. Petrossians, P. Heliövaara, E. Jaffrain-Rea, M.-L. Barlier, A. Naves, L.A. Ebeling, T. Karhu, A. Raappana, A. Cazabat, L. De Menis, E. Montañana, C.F. Raverot, G. Weil, R.J. Sane, T. Maiter, D. Neggers, S. Yaneva, M. Tabarin, A. Verrua, E. Eloranta, E. Murat, A. Vierimaa, O. Salmela, P.I. Emy, P. Toledo, R.A. Sabaté, M.I. Villa, C. Popelier, M. Salvatori, R. Jennings, J. Longás, Á.F. Aizpún, J.I.L. Georgitsi, M. Paschke, R. Ronchi, C. Valimaki, M. Saloranta, C. De Herder, W. Cozzi, R. Guitelman, M. Magri, F. Lagonigro, M.S. Halaby, G. Corman, V. Hagelstein, M.-T. Vanbellinghen, J.-F. Barra, G.B. Gimenez-Roqueplo, A.-P. Cameron, F.J. Borson-Chazot, F. Holdaway, I. Toledo, S.P.A. Stalla, G.K. Spada, A. Zacharieva, S. Bertherat, J. Brue, T. Bours, V. Chanson, P. Aaltonen, L.A. Beckers, A. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study |
| topic_facet |
growth hormone liothyronine octreotide somatomedin C somatostatin derivative thyrotropin thyroxine adult aip gene article cancer invasion clinical assessment controlled study dyspnea female gene mutation genetic predisposition genotype phenotype correlation germ line gigantism growth hormone blood level growth hormone secreting adenoma human human genome hypophysis adenoma hypopituitarism liothyronine blood level major clinical study male onset age priority journal prolactin release prolactinoma repeated drug dose retrospective study tachycardia thyrotropin blood level thyrotropin secreting adenoma thyroxine blood level treatment response tumor volume |
| description |
Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. Design: This study was an international, multicenter, retrospective case collection/database analysis. Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. Copyright © 2010 by The Endocrine Society. |
| format |
JOUR |
| author |
Daly, A.F. Tichomirowa, M.A. Petrossians, P. Heliövaara, E. Jaffrain-Rea, M.-L. Barlier, A. Naves, L.A. Ebeling, T. Karhu, A. Raappana, A. Cazabat, L. De Menis, E. Montañana, C.F. Raverot, G. Weil, R.J. Sane, T. Maiter, D. Neggers, S. Yaneva, M. Tabarin, A. Verrua, E. Eloranta, E. Murat, A. Vierimaa, O. Salmela, P.I. Emy, P. Toledo, R.A. Sabaté, M.I. Villa, C. Popelier, M. Salvatori, R. Jennings, J. Longás, Á.F. Aizpún, J.I.L. Georgitsi, M. Paschke, R. Ronchi, C. Valimaki, M. Saloranta, C. De Herder, W. Cozzi, R. Guitelman, M. Magri, F. Lagonigro, M.S. Halaby, G. Corman, V. Hagelstein, M.-T. Vanbellinghen, J.-F. Barra, G.B. Gimenez-Roqueplo, A.-P. Cameron, F.J. Borson-Chazot, F. Holdaway, I. Toledo, S.P.A. Stalla, G.K. Spada, A. Zacharieva, S. Bertherat, J. Brue, T. Bours, V. Chanson, P. Aaltonen, L.A. Beckers, A. |
| author_facet |
Daly, A.F. Tichomirowa, M.A. Petrossians, P. Heliövaara, E. Jaffrain-Rea, M.-L. Barlier, A. Naves, L.A. Ebeling, T. Karhu, A. Raappana, A. Cazabat, L. De Menis, E. Montañana, C.F. Raverot, G. Weil, R.J. Sane, T. Maiter, D. Neggers, S. Yaneva, M. Tabarin, A. Verrua, E. Eloranta, E. Murat, A. Vierimaa, O. Salmela, P.I. Emy, P. Toledo, R.A. Sabaté, M.I. Villa, C. Popelier, M. Salvatori, R. Jennings, J. Longás, Á.F. Aizpún, J.I.L. Georgitsi, M. Paschke, R. Ronchi, C. Valimaki, M. Saloranta, C. De Herder, W. Cozzi, R. Guitelman, M. Magri, F. Lagonigro, M.S. Halaby, G. Corman, V. Hagelstein, M.-T. Vanbellinghen, J.-F. Barra, G.B. Gimenez-Roqueplo, A.-P. Cameron, F.J. Borson-Chazot, F. Holdaway, I. Toledo, S.P.A. Stalla, G.K. Spada, A. Zacharieva, S. Bertherat, J. Brue, T. Bours, V. Chanson, P. Aaltonen, L.A. Beckers, A. |
| author_sort |
Daly, A.F. |
| title |
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study |
| title_short |
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study |
| title_full |
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study |
| title_fullStr |
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study |
| title_full_unstemmed |
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: An international collaborative study |
| title_sort |
clinical characteristics and therapeutic responses in patients with germ-line aip mutations and pituitary adenomas: an international collaborative study |
| url |
http://hdl.handle.net/20.500.12110/paper_0021972X_v95_n11_pE373_Daly |
| work_keys_str_mv |
AT dalyaf clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT tichomirowama clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT petrossiansp clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT heliovaarae clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT jaffrainreaml clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT barliera clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT navesla clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT ebelingt clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT karhua clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT raappanaa clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT cazabatl clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT demenise clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT montananacf clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT raverotg clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT weilrj clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT sanet clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT maiterd clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT neggerss clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT yanevam clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT tabarina clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT verruae clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT elorantae clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT murata clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT vierimaao clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT salmelapi clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT emyp clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT toledora clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT sabatemi clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT villac clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT popelierm clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT salvatorir clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT jenningsj clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT longasaf clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT aizpunjil clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT georgitsim clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT paschker clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT ronchic clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT valimakim clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT salorantac clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT deherderw clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT cozzir clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT guitelmanm clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT magrif clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT lagonigroms clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT halabyg clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT cormanv clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT hagelsteinmt clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT vanbellinghenjf clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT barragb clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT gimenezroqueploap clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT cameronfj clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT borsonchazotf clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT holdawayi clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT toledospa clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT stallagk clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT spadaa clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT zacharievas clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT bertheratj clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT bruet clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT boursv clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT chansonp clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT aaltonenla clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy AT beckersa clinicalcharacteristicsandtherapeuticresponsesinpatientswithgermlineaipmutationsandpituitaryadenomasaninternationalcollaborativestudy |
| _version_ |
1782025630395662336 |